Tested HDV-insulin to reduce your body’s own glucose release
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This Phase 1 study tests an injectable HDV-insulin lispro to see how well it can reduce how much glucose your body makes on its own in people with type 1 diabetes. It is mainly focused on safety and finding the right dose range.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old
- You have had type 1 diabetes for at least 12 months
- Your C-peptide blood test is very low (≤0.8 ng/mL, one repeat test allowed)
- Your BMI is between 18.0 and 33.0
- Your most recent HbA1c is between 6.5% and 8.5%
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a system that measures blood sugar and automatically adjusts insulin delivery. It is for adults with type 1 diabetes who use insulin injections or a pump.
This study tests a new way to give insulin directly into the abdomen (intraperitoneal) for people with type 1 diabetes. It will check how safe and effective a single dose is over 12 hours, using a special procedure to keep blood sugar stable (clamp).
This study compares a new automated insulin delivery algorithm (AIDANET) in two modes: fully closed-loop (no user input needed) versus hybrid closed-loop (user still gives some insulin for meals). It tests how well the algorithm works in real-life settings for adults with type 1 diabetes.
This study tests a new once-weekly injectable medication (HDM1005) for people with type 2 diabetes whose blood sugar is not well controlled by diet and exercise or metformin alone. It aims to help lower blood sugar and may also support weight loss.
This trial tests a new medicine called HDM1005 for people with type 2 diabetes who haven't been helped enough by diet and exercise alone, and who haven't taken any diabetes medication in the last 12 weeks. It aims to see if the medicine can help lower blood sugar levels safely.
This study is testing a new injectable medication (IN-B00009) to see if it helps lower blood sugar in people with type 2 diabetes who are not currently on diabetes medicine. It might be an option if diet and exercise alone are not enough to control your diabetes.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.